Latest Period
Q1 2026
Security Snapshot
NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) Institutional Ownership
CUSIP: 640268306
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
202
Shares (Excl. Options)
26,436,045
Price
$71.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- NKTR on Nasdaq
- Shares outstanding
- 28,687,922
- Price per share
- $91.26
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 26,436,045
- Total reported value
- $1,900,394,199
- % of total 13F portfolios
- 0.01%
- Share change
- +8,895,418
- Value change
- +$680,386,126
- Number of holders
- 202
- Price from insider filings
- $91.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NKTR - NEKTAR THERAPEUTICS - COMMON STOCK is tracked under CUSIP 640268306.
- 202 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 171 to 202 between Q4 2025 and Q1 2026.
- Reported value moved from $731,897,039 to $1,900,394,199.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 202 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 640268306?
CUSIP 640268306 identifies NKTR - NEKTAR THERAPEUTICS - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640268306:
Significant Owners of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +35% | $331,302,473 | +$97,502,292 | 4,303,188 | +42% | FMR LLC | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 7.4% | $32,978,662 | 1,276,595 | BVF PARTNERS L P/IL | 01 Jul 2025 | |||
| VANGUARD GROUP INC | 5% | +1.2% | $43,425,528 | +$3,316,543 | 1,027,089 | +8.3% | The Vanguard Group | 31 Dec 2025 |
| SUSQUEHANNA SECURITIES, LLC | 4% | -38% | $34,245,405 | -$18,006,925 | 809,967 | -34% | G1 Execution Services, LLC | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 3% | -48% | $32,489,559 | -$20,590,346 | 570,994 | -39% | Millennium Management LLC | 30 Sep 2025 |
| Nantahala Capital Management, LLC | 2.2% | -59% | $23,813,902 | -$16,571,499 | 418,522 | -41% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| BlackRock, Inc. | 1.6% | $5,245,655 | 203,017 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 202 institutional investors reported holding 26,436,045 shares of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR). This represents 92% of the company’s total 28,687,922 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,303,188 | +4155% | 0.02% | $309,614,403 |
| BVF INC/IL | 8.9% | 2,559,595 | +64% | 5.9% | $184,162,860 |
| Two Seas Capital LP | 6.8% | 1,959,178 | +163% | 6.5% | $140,962,857 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,197,055 | 0% | 0% | $86,128,107 |
| TWO SIGMA INVESTMENTS, LP | 3.2% | 930,741 | +97% | 0.06% | $66,966,815 |
| Prosight Management, LP | 2.6% | 735,000 | +33% | 8.7% | $52,883,250 |
| BlackRock, Inc. | 2.4% | 692,650 | +7.3% | 0% | $49,836,168 |
| MORGAN STANLEY | 2.3% | 659,387 | +16% | 0% | $47,442,895 |
| ARMISTICE CAPITAL, LLC | 2% | 578,000 | -3% | 1.4% | $41,587,100 |
| Invesco Ltd. | 2% | 567,458 | +21% | 0.01% | $40,828,603 |
| CITADEL ADVISORS LLC | 1.8% | 513,531 | +66% | 0.03% | $36,948,555 |
| Sofinnova Investments, Inc. | 1.8% | 509,546 | +16% | 1.8% | $36,661,835 |
| Woodline Partners LP | 1.4% | 415,335 | +299% | 0.11% | $29,883,353 |
| LORD, ABBETT & CO. LLC | 1.4% | 405,080 | 0.1% | $29,146,000 | |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 404,277 | -11% | 0.02% | $29,087,730 |
| EMERALD ADVISERS, LLC | 1.4% | 394,604 | +2.7% | 0.9% | $28,391,758 |
| Qube Research & Technologies Ltd | 1.4% | 390,675 | +21% | 0.04% | $28,109,066 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 346,795 | +36% | 0% | $24,961,900 |
| UBS Group AG | 1.1% | 320,172 | +11% | 0% | $23,036,375 |
| GREAT POINT PARTNERS LLC | 1.1% | 316,453 | +50% | 5.6% | $22,768,793 |
| Vestal Point Capital, LP | 0.99% | 285,000 | 0.57% | $20,505,750 | |
| 22NW, LP | 0.98% | 281,115 | -15% | 16% | $20,226,224 |
| PRIMECAP MANAGEMENT CO/CA/ | 0.97% | 279,150 | -0.36% | 0.02% | $20,084,842 |
| ORBIMED ADVISORS LLC | 0.96% | 275,000 | 0.45% | $19,786,250 | |
| GILDER GAGNON HOWE & CO LLC | 0.95% | 271,758 | +30% | 0.23% | $19,552,988 |
Institutional Holders of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,436,045 | $1,900,394,199 | +$680,386,126 | $71.95 | 202 |
| 2025 Q4 | 17,311,424 | $731,897,039 | +$83,234,784 | $42.28 | 171 |
| 2025 Q3 | 14,405,809 | $819,769,158 | +$416,306,829 | $56.90 | 143 |
| 2025 Q2 | 7,657,053 | $197,846,106 | +$197,839,388 | $25.84 | 100 |